[Detection of KRAS mutations: evolution or revolution for the pathologists?].
Bibeau
Frédéric
F
Penault-Llorca
Frédérique
F
Sabourin
Jean-Christophe
JC
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000276:immunology / Q000473:pathology; D000068818:Cetuximab; D066246:ErbB Receptors / Q000276:immunology; D005260:Female; D006801:Humans; D009154:Mutation; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D020133:Reverse Transcriptase Polymerase Chain Reaction; D000068878:Trastuzumab; D018631:ras Proteins / Q000235:genetics*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068878:Trastuzumab; D000068818:Cetuximab